[18F]MC225 PET to Evaluate Gender Differences in BBB P-gp Function
The Impact of Gender Differences in P-glycoprotein Function Measured With [18F]MC225 and PET
1 other identifier
interventional
10
0 countries
N/A
Brief Summary
P-gp is one of the main efflux transporters at the blood-brain barrier and is responsible for the transport of a variety of neurotoxic substances, including pharmaceuticals. Multiple studies report gender differences in therapeutic outcomes, toxicity and side effects for many drug agents. P-gp plays an important role in the bio-availability, drug distribution, metabolism and elimination of pharmaceuticals labelled as P-gp substrates (e.g. the majority of antidepressants and antipsychotics). A difference in P-gp function was already reported in hepatic P-gp expression. The aim of the current study is to evaluate the influence of gender on cerebral P-gp function. Outcomes of this study can be of great importance in gender-based prescription of P-gp substrate pharmaceuticals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2023
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 8, 2022
CompletedFirst Posted
Study publicly available on registry
November 16, 2022
CompletedStudy Start
First participant enrolled
January 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2025
CompletedNovember 16, 2022
November 1, 2022
1 year
November 8, 2022
November 8, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
PET kinetic modeling outcome parameters [18F]MC225
volume of distribution, K1, k2
60 minutes after administration [18F]MC225
Secondary Outcomes (1)
PET kinetic modeling outcome parameters [15O]H2O
10 minutes after administration of [15O]H2O
Study Arms (2)
Male
ACTIVE COMPARATOR5 male participants will undergo a \[18F\]MC225 PET scan
Female
ACTIVE COMPARATOR5 female participants will undergo a \[18F\]MC225 PET scan
Interventions
Eligibility Criteria
You may qualify if:
- Healthy volunteers
You may not qualify if:
- Use of medication with a known effect on the BBB P-glycoprotein transporter
- Any history of neurological or psychiatric conditions affecting the BBB P-glycoprotein function
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Salvi de Souza G, Mossel P, Somsen JF, Providencia L, Bartels AL, Willemsen ATM, Dierckx RAJO, Furini CRG, Lammertsma AA, Tsoumpas C, Luurtsema G. Evaluating image-derived input functions for cerebral [18F]MC225 PET studies. Front Nucl Med. 2025 Jun 5;5:1597902. doi: 10.3389/fnume.2025.1597902. eCollection 2025.
PMID: 40538986DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof.
Study Record Dates
First Submitted
November 8, 2022
First Posted
November 16, 2022
Study Start
January 1, 2023
Primary Completion
January 1, 2024
Study Completion
January 1, 2025
Last Updated
November 16, 2022
Record last verified: 2022-11
Data Sharing
- IPD Sharing
- Will not share